摘要
急性髓系白血病(非M3)恶性程度高,部分患者经传统蒽环类药物联合阿糖胞苷的3+7方案诱导后不能达到完全缓解,预后不佳。本文概括AML初次诱导后疗效检测与评估方法,总结追加再诱导方案(中、大剂量Ara-C为基础的方案、FLAG方案、标准剂量Ara-C+蒽环或蒽醌类药物、含G-CSF的预激方案),探讨后续治疗的现状。
Acute myeloid leukemia（ non-M3） is highly malignant. Some patients can not achieve complete remission after induction which traditional 3 ＋ 7 regimen,anthracycline combined with cytarabine,suggesting poor prognosis.This paper reviews the effect test and evaluation method after first induction,and summarizes reinduction chemotherapy（ intermediate/large doses of Ara-C-based regimen,FLAG,standard dose of Ara-C ＋ anthracycline or anthraquinone drugs,G-CSF-containing regimen） to study the current situation of later treatment.
作者
杨融辉
马欢欣
高欣
沈静
廖爱军
YANG Rong-hui;MA Huan-xin;GAO Xin;SHEN Jing;LIAO Ai-jun(Department of Hematology, Shengjing Hospital of China Medical University, Shenyang 110004, China)
出处
《实用药物与临床》
CAS
2018年第5期577-580,共4页
Practical Pharmacy and Clinical Remedies
基金
国家自然科学基金(81272629)
沈阳市科技计划项目(17-231-1-58)
关键词
急性髓系白血病
初次诱导失败
治疗现状
Acute myeloid leukemia
First induction failure
Treatment status
